- Patient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation — Recruiting • Cardiology / Cardiovascular • NCT07852221.
- What is being tested: The pace-and-ablate strategy (atrioventricular node ablation with permanent pacing) in patients with drug-refractory or ablation-refractory atrial fibrillation, with particular focus on long-term outcomes and development of pacing-induced cardiomyopathy.
- Patient eligibility overview: Adults with atrial fibrillation who have failed medical rate-control therapy and/or catheter ablation attempts, requiring alternative intervention to control ventricular rate.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Atrioventricular node ablation with permanent pacing (the "pace-and-ablate" strategy) controls ventricular rate in atrial fibrillation that has not responded to drug therapy or catheter ablation. Chronic right ventricular pacing, however, can cause pacing-induced cardiomyopathy (PICM), and it is not well established which patients are at risk and should therefore receive conduction system pacing or biventricular pacing instead. REPACE is a multicentre retrospective cohort of consecutive patients who underwent atrioventricular node ablation from January 2011 onwards at five centres in Switzerland, the United Kingdom and Poland: Liverpool Heart and Chest Hospital,…
- : * Age 18 years or older at the time of atrioventricular node ablation * Atrial fibrillation, undergoing atrioventricular node ablation with a permanent cardiac implantable electronic device already in situ or implanted as part of the pace-and-ablate strategy * Availability of baseline echocardiographic data, including left ventricular ejection fraction
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.